Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kwality PharmaceuticalsNSE:KPL +5.15%60 Return-on-Tangible-Asset is 17.48% as of Jun. 2026, which is 141% above its 10-year median of 7.24. GuruFocus rates NSE:KPL with a GF Score™ of 60/100 and a GF Value™ of ₹1,332.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Kwality Pharmaceuticals ranks better than 89.66% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kwality Pharmaceuticals's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹1,025 Mil. Kwality Pharmaceuticals's average total tangible assets for the quarter that ended in Jun. 2026 was ₹5,864 Mil. Therefore, Kwality Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 17.48%.
The historical rank and industry rank for Kwality Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
NSE:KPL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.44 Med: 7.24 Max: 47.35
Current: 16.12
During the past 13 years, Kwality Pharmaceuticals's highest Return-on-Tangible-Asset was 47.35%. The lowest was 5.44%. And the median was 7.24%.
NSE:KPL's Return-on-Tangible-Asset is ranked better than 89.66% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.085
vs NSE:KPL: 16.12
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kwality Pharmaceuticals Return-on-Tangible-Asset Related Terms
Kwality Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kwality Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kwality Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kwality Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kwality Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kwality Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 17.48% mean?
Kwality Pharmaceuticals (NSE:KPL) has a Return-on-Tangible-Asset of 17.48% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kwality Pharmaceuticals and its competitors. This is 141% above median its historical median of 7.24. Over the past decade, Kwality Pharmaceuticals' Return-on-Tangible-Asset has ranged from 5.44 to 47.35. According to the industry distribution chart, Kwality Pharmaceuticals ranks #104 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 10.3%.
Is Kwality Pharmaceuticals' Return-on-Tangible-Asset too high?
Kwality Pharmaceuticals' current Return-on-Tangible-Asset of 17.48% is 141% above median its 10-year median of 7.24. Over the past 10 years, this metric has ranged from a low of 5.44 to a high of 47.35. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.09. Kwality Pharmaceuticals' value of 17.48% is 466.6% above this industry median. Based on the distribution chart, Kwality Pharmaceuticals ranks #104 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kwality Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' Return-on-Tangible-Asset compare to ?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #104 out of 1006 companies for Return-on-Tangible-Asset. This places Kwality Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.09. Kwality Pharmaceuticals' value of 17.48% is 466.6% above this benchmark. Historically, Kwality Pharmaceuticals' own Return-on-Tangible-Asset has ranged from 5.44 to 47.35 over the past decade. While the company's 10-year median is 7.24 vs. the industry median of 3.09, Kwality Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.09, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kwality Pharmaceuticals's current Return-on-Tangible-Asset of 17.48% is 466.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kwality Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kwality Pharmaceuticals's current Return-on-Tangible-Asset is 17.48%, which is 141% above median its own 10-year median of 7.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (NSE:KPL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,332.01, compared to a current price of ₹3,630.30 — trading 172.5% above its estimated fair value. The current Return-on-Tangible-Asset is 17.48%, which is 141% above median its 10-year median of 7.24 and 466.6% above the Drug Manufacturers industry median of 3.09. Kwality Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kwality Pharmaceuticals (NSE:KPL), the current Return-on-Tangible-Asset is 17.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (NSE:KPL) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹3,630.30 is trading 172.5% above its estimated GF Value™ of ₹1,332.01.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:KPL:
Return-on-Tangible-Asset: 17.48% (141% above median its 10-year median of 7.24)
GF Value™: ₹1,332.01 vs. price of ₹3,630.30 (172.5% above fair value)
Industry Position: 466.6% above the Drug Manufacturers median (#104 of 1006)
No single metric tells the full story. See the NSE:KPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
60GF Score
Get the complete analysis for NSE:KPL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KPL has been successfully added to your 
